BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12944056)

  • 21. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    Fournier A; Oprisiu R; Andrejak M; Fernandez L; Achard JM
    JAMA; 2003 Feb; 289(6):700; author reply 701. PubMed ID: 12585946
    [No Abstract]   [Full Text] [Related]  

  • 22. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    Messerli FH; Grossman E; Fournier A
    JAMA; 2003 Feb; 289(6):700-1; author reply 701. PubMed ID: 12585945
    [No Abstract]   [Full Text] [Related]  

  • 23. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Cruickshank JM
    Lancet; 2002 Jun; 359(9324):2200-1; author reply 2203-4. PubMed ID: 12091004
    [No Abstract]   [Full Text] [Related]  

  • 25. [LIFE study proves preventive action. With losartan to do even more against stroke].
    Baumgart P
    MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
    [No Abstract]   [Full Text] [Related]  

  • 26. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
    [No Abstract]   [Full Text] [Related]  

  • 27. INVEST study adds important data for clinical practice in new-onset diabetes.
    Cardiovasc J S Afr; 2004; 15(4):195. PubMed ID: 15322579
    [No Abstract]   [Full Text] [Related]  

  • 28. ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
    Geriatrics; 2002 May; 57(5):63-4. PubMed ID: 12040595
    [No Abstract]   [Full Text] [Related]  

  • 29. Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone?
    Schillaci G; Pirro M; Mannarino E
    Hypertension; 2007 Nov; 50(5):851-3. PubMed ID: 17893369
    [No Abstract]   [Full Text] [Related]  

  • 30. [Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
    Schmieder RE; Schneider MP
    MMW Fortschr Med; 2002 Oct; 144(42):45-6. PubMed ID: 12533997
    [No Abstract]   [Full Text] [Related]  

  • 31. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
    Bourassa MG
    J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
    [No Abstract]   [Full Text] [Related]  

  • 32. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diuretics in the LIFE study.
    Kato J; Eto T
    Lancet; 2004 Jul 31-Aug 6; 364(9432):413; author reply 413-4. PubMed ID: 15288732
    [No Abstract]   [Full Text] [Related]  

  • 34. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Hamon M
    Lancet; 2002 Jun; 359(9324):2199-200; author reply 2203-4. PubMed ID: 12091003
    [No Abstract]   [Full Text] [Related]  

  • 35. [LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
    Heinzl S
    Med Monatsschr Pharm; 2002 May; 25(5):149. PubMed ID: 12050919
    [No Abstract]   [Full Text] [Related]  

  • 36. [Kidney protection leads to heart protection, too].
    MMW Fortschr Med; 2006 Aug; 148(33-34):57. PubMed ID: 16981393
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Plus point -- risk reduction].
    MMW Fortschr Med; 2006 Aug; 148(33-34):56-7. PubMed ID: 16981392
    [No Abstract]   [Full Text] [Related]  

  • 40. [Optimizing antihypertensive therapy. In 5 years 35,000 strokes are preventable].
    MMW Fortschr Med; 2004 Jul; 146(27-28):52. PubMed ID: 15526671
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.